메뉴 건너뛰기




Volumn 114, Issue 4, 2019, Pages 363-373

Canadian expert consensus: management of hypersensitivity reactions to intravenous iron in adults

Author keywords

anaphylaxis; consensus; hypersensitivity reactions; intravenous iron

Indexed keywords

IRON; FERRYL IRON;

EID: 85063670820     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12773     Document Type: Article
Times cited : (37)

References (46)
  • 1
    • 84908459097 scopus 로고    scopus 로고
    • Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management
    • Rampton D, Folkersen J, Fishbane S, et al.: Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica 2014; 99:1671–1676
    • (2014) Haematologica , vol.99 , pp. 1671-1676
    • Rampton, D.1    Folkersen, J.2    Fishbane, S.3
  • 2
    • 85041104035 scopus 로고    scopus 로고
    • The safety of available treatment options for iron-deficiency anemia
    • Muñoz M, Gómez-Ramírez S, Bhandari S: The safety of available treatment options for iron-deficiency anemia. Expert Opin Drug Saf 2018; 17:149–159
    • (2018) Expert Opin Drug Saf , vol.17 , pp. 149-159
    • Muñoz, M.1    Gómez-Ramírez, S.2    Bhandari, S.3
  • 3
    • 84899689238 scopus 로고    scopus 로고
    • EMEA/H/A-31/1322. European Medicines Agency,, [Last accessed July 15, 2018] Available from
    • European Medicines Agency: Assessment report for: Iron containing intravenous (IV) medicinal products. EMEA/H/A-31/1322. European Medicines Agency, 2013 [Last accessed: July 15, 2018] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/IV_iron_31/WC500150771.pdf.
    • (2013) Assessment report for: Iron containing intravenous (IV) medicinal products
  • 4
    • 77952118055 scopus 로고    scopus 로고
    • [Last accessed January 17, 2019] Available from
    • Ferinject (Ferric Carboxymaltose): Summary of Product Characteristics. [Last accessed: January 17, 2019] Available from: https://www.medicines.org.uk/emc/medicine/5910.
    • Summary of Product Characteristics
  • 5
    • 34547464547 scopus 로고    scopus 로고
    • [Last accessed January 17, 2019] Available from
    • Injectafer (Ferric Carboxymaltose Injection): Full Prescribing Information. [Last accessed: January 17, 2019] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203565s000lbl.pdf.
    • Full Prescribing Information
  • 6
    • 77952118055 scopus 로고    scopus 로고
    • [Last accessed January 17, 2019] Available from
    • Rienso (Ferumoxytol): Summary of Product Characteristics. [Last accessed: January 17, 2019] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002215/WC500129749.pdf.
    • Summary of Product Characteristics
  • 7
    • 84939265322 scopus 로고    scopus 로고
    • [Last accessed January 17, 2019] Available from
    • Feraheme (Ferumoxytol): Injection Full Prescribing Information. [Last accessed: January 17, 2019] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022180lbl.pdf.
    • Injection Full Prescribing Information
  • 8
    • 77952118055 scopus 로고    scopus 로고
    • [Last accessed January 17, 2019] Available from
    • Monofer (Iron [III] Isomaltoside 1000): Summary of Product Characteristics. [Last accessed: January 17, 2019] Available from: https://www.medicines.org.uk/emc/product/5676/smpc#PHARMACOLOGICAL_PROPS.
    • Summary of Product Characteristics
  • 9
    • 85063675534 scopus 로고    scopus 로고
    • Kirkland, QC, Pfizer Canada Inc.,, [Last accessed January 22, 2019] Available from
    • Monoferric (Iron Isomaltoside 1000 for Injection): Product Monograph. Kirkland, QC, Pfizer Canada Inc., 2018[Last accessed: January 22, 2019] Available from: https://www.pfizer.ca/sites/g/files/g10050796/f/201810/MONOFERRIC_PM_E_193890_22JUN2018.pdf.
    • (2018) Product Monograph
  • 10
    • 84904512880 scopus 로고    scopus 로고
    • Mississauga, ON, Bellco Health Care Inc.,, [Last accessed January 17, 2019] Available from
    • Venofer (Iron Sucrose Injection): Product Monograph. Mississauga, ON, Bellco Health Care Inc., 2013[Last accessed: January 17, 2019] Available from: https://pdf.hres.ca/dpd_pm/00018889.PDF.
    • (2013) Product Monograph
  • 11
    • 77952118055 scopus 로고    scopus 로고
    • [Last accessed January 17, 2019] Available from
    • Venofer (Iron Sucrose): Summary of Product Characteristics. [Last accessed: January 17, 2019] Available from: https://www.medicines.org.uk/emc/product/5911/smpc.
    • Summary of Product Characteristics
  • 12
    • 34547464547 scopus 로고    scopus 로고
    • [Last accessed January 17, 2019] Available from
    • Venofer (Iron Sucrose Injection): Full Prescribing Information. [Last accessed: January 17, 2019] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021135s017lbl.pdf.
    • Full Prescribing Information
  • 13
    • 85054726232 scopus 로고    scopus 로고
    • Mississauga, ON, Bellco Health Care Inc.,, [Last accessed January 17, 2019] Available from
    • DexIron (Iron Dextran Injection): Product Monograph. Mississauga, ON, Bellco Health Care Inc., 2017[Last accessed: January 17, 2019] Available from: https://pdf.hres.ca/dpd_pm/00037716.PDF.
    • (2017) Product Monograph
  • 14
    • 77952118055 scopus 로고    scopus 로고
    • [Last accessed January 17, 2019] Available from
    • CosmoFer (Iron Dextran): Summary of Product Characteristics. [Last accessed: January 17, 2019] Available from: https://www.medicines.org.uk/emc/product/48/smpc#POSOLOGY.
    • Summary of Product Characteristics
  • 15
    • 34547464547 scopus 로고    scopus 로고
    • [Last accessed January 17, 2019] Available from
    • INFeD (Iron Dextran Injection): Full Prescribing Information. [Last accessed: January 17, 2019] Available from: https://www.allergan.com/assets/pdf/infed_pi.
    • Full Prescribing Information
  • 16
    • 85036517771 scopus 로고    scopus 로고
    • Laval, QC, sanofi-aventis Canada Inc.,, [Last accessed January 17, 2019] Available from
    • Ferrlecit (Sodium Ferric Gluconate Complex in Sucrose Injection): Product Monograph. Laval, QC, sanofi-aventis Canada Inc., 2016[Last accessed: January 17, 2019] Available from: https://pdf.hres.ca/dpd_pm/00037569.PDF.
    • (2016) Product Monograph
  • 17
    • 34547464547 scopus 로고    scopus 로고
    • [Last accessed January 17, 2019] Available from
    • Ferrlecit (Sodium Ferric Gluconate Complex in Sucrose Injection): Full Prescribing Information. [Last accessed: January 17, 2019] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020955s013s015lbl.pdf.
    • Full Prescribing Information
  • 18
    • 79954432935 scopus 로고    scopus 로고
    • World Allergy Organization guidelines for the assessment and management of anaphylaxis
    • Simons FE, Ardusso LR, Bilò MB, et al.: World Allergy Organization guidelines for the assessment and management of anaphylaxis. World Allergy Organ J 2011; 4:13–37
    • (2011) World Allergy Organ J , vol.4 , pp. 13-37
    • Simons, F.E.1    Ardusso, L.R.2    Bilò, M.B.3
  • 19
    • 84946037337 scopus 로고    scopus 로고
    • 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines
    • Simons FE, Ebisawa M, Sanchez-Borges M, et al.: 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines. World Allergy Organ J 2015; 8:32
    • (2015) World Allergy Organ J , vol.8 , pp. 32
    • Simons, F.E.1    Ebisawa, M.2    Sanchez-Borges, M.3
  • 21
    • 77956430490 scopus 로고    scopus 로고
    • Glucocorticoids for the treatment of anaphylaxis: cochrane systematic review
    • Choo KJ, Simon E, Sheikh A: Glucocorticoids for the treatment of anaphylaxis: cochrane systematic review. Allergy 2010; 65:1205–1211
    • (2010) Allergy , vol.65 , pp. 1205-1211
    • Choo, K.J.1    Simon, E.2    Sheikh, A.3
  • 22
    • 84879159167 scopus 로고    scopus 로고
    • Epinephrine: the drug of choice for anaphylaxis-a statement of the World Allergy Organization
    • Kemp SF, Lockey RF, Simons FE, et al.: Epinephrine: the drug of choice for anaphylaxis-a statement of the World Allergy Organization. World Allergy Organ J 2008; 1(7 Suppl):S18–S26
    • (2008) World Allergy Organ J , vol.1 , Issue.7 , pp. S18-S26
    • Kemp, S.F.1    Lockey, R.F.2    Simons, F.E.3
  • 23
    • 85048001207 scopus 로고    scopus 로고
    • The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
    • Zuberbier T, Aberer W, Asero R, et al.: The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 2018; 73:1393–1414
    • (2018) Allergy , vol.73 , pp. 1393-1414
    • Zuberbier, T.1    Aberer, W.2    Asero, R.3
  • 24
    • 85028506249 scopus 로고    scopus 로고
    • Acute and chronic urticaria: evaluation and treatment
    • Schaefer P: Acute and chronic urticaria: evaluation and treatment. Am Fam Physician 2017; 95:717–724
    • (2017) Am Fam Physician , vol.95 , pp. 717-724
    • Schaefer, P.1
  • 25
    • 84899496074 scopus 로고    scopus 로고
    • The diagnosis and management of acute and chronic urticaria: 2014 update
    • Bernstein JA, Lang DM, Khan DA, et al.: The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol 2014; 133:1270–1277
    • (2014) J Allergy Clin Immunol , vol.133 , pp. 1270-1277
    • Bernstein, J.A.1    Lang, D.M.2    Khan, D.A.3
  • 27
    • 85043357925 scopus 로고    scopus 로고
    • Factors increasing the risk for a severe reaction in anaphylaxis: an analysis of data from The European Anaphylaxis Registry
    • Worm M, Francuzik W, Renaudin JM, et al.: Factors increasing the risk for a severe reaction in anaphylaxis: an analysis of data from The European Anaphylaxis Registry. Allergy 2018; 73:1322–1330
    • (2018) Allergy , vol.73 , pp. 1322-1330
    • Worm, M.1    Francuzik, W.2    Renaudin, J.M.3
  • 28
    • 84973130364 scopus 로고    scopus 로고
    • Iron management in chronic kidney disease: conclusions from a “Kidney Disease: improving Global Outcomes” (KDIGO) Controversies Conference
    • Macdougall IC, Bircher AJ, Eckardt KU, et al.: Iron management in chronic kidney disease: conclusions from a “Kidney Disease: improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int 2016; 89:28–39
    • (2016) Kidney Int , vol.89 , pp. 28-39
    • Macdougall, I.C.1    Bircher, A.J.2    Eckardt, K.U.3
  • 29
    • 84945930081 scopus 로고    scopus 로고
    • Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management
    • Szebeni J, Fishbane S, Hedenus M, et al.: Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management. Br J Pharmacol 2015; 172:5025–5036
    • (2015) Br J Pharmacol , vol.172 , pp. 5025-5036
    • Szebeni, J.1    Fishbane, S.2    Hedenus, M.3
  • 31
    • 84947431101 scopus 로고    scopus 로고
    • Comparative risk of anaphylactic reactions associated with intravenous iron products
    • Wang C, Graham DJ, Kane RC, et al.: Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA 2015; 314:2062–2068
    • (2015) JAMA , vol.314 , pp. 2062-2068
    • Wang, C.1    Graham, D.J.2    Kane, R.C.3
  • 32
    • 0029795844 scopus 로고    scopus 로고
    • The safety of intravenous iron dextran in hemodialysis patients
    • Fishbane S, Ungureanu VD, Maesaka JK, et al.: The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996; 28:529–534
    • (1996) Am J Kidney Dis , vol.28 , pp. 529-534
    • Fishbane, S.1    Ungureanu, V.D.2    Maesaka, J.K.3
  • 33
    • 0028138372 scopus 로고
    • Safe administration of iron dextran to a patient who reacted to the test dose
    • Monaghan MS, Glasco G, St John G, et al.: Safe administration of iron dextran to a patient who reacted to the test dose. South Med J 1994; 87:1010–1012
    • (1994) South Med J , vol.87 , pp. 1010-1012
    • Monaghan, M.S.1    Glasco, G.2    St John, G.3
  • 34
    • 34047200850 scopus 로고    scopus 로고
    • Safe administration of iron sucrose in a patient with a previous hypersensitivity reaction to ferric gluconate
    • Sane R, Baribeault D, Rosenberg CL: Safe administration of iron sucrose in a patient with a previous hypersensitivity reaction to ferric gluconate. Pharmacother 2007; 27:613–615
    • (2007) Pharmacother , vol.27 , pp. 613-615
    • Sane, R.1    Baribeault, D.2    Rosenberg, C.L.3
  • 35
    • 0034725897 scopus 로고    scopus 로고
    • Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation
    • Barton JC, Barton EH, Bertoli LF, et al.: Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation. Am J Med 2000; 109:27–32
    • (2000) Am J Med , vol.109 , pp. 27-32
    • Barton, J.C.1    Barton, E.H.2    Bertoli, L.F.3
  • 36
    • 28544441741 scopus 로고    scopus 로고
    • Acute hypersensitivity reaction to ferric gluconate in a premedicated patient
    • Saadeh CE, Srkalovic G: Acute hypersensitivity reaction to ferric gluconate in a premedicated patient. Ann Pharmacother 2005; 39:2124–2127
    • (2005) Ann Pharmacother , vol.39 , pp. 2124-2127
    • Saadeh, C.E.1    Srkalovic, G.2
  • 37
    • 84904690812 scopus 로고    scopus 로고
    • Safety of intravenous iron formulations: facts and folklore
    • Auerbach M, Macdougall IC: Safety of intravenous iron formulations: facts and folklore. Blood Transfus 2014; 12:296–300
    • (2014) Blood Transfus , vol.12 , pp. 296-300
    • Auerbach, M.1    Macdougall, I.C.2
  • 38
    • 0035057037 scopus 로고    scopus 로고
    • Suspected iron dextran-related adverse drug events in hemodialysis patients
    • Fletes R, Lazarus JM, Gage J, et al.: Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis 2001; 37:743–749
    • (2001) Am J Kidney Dis , vol.37 , pp. 743-749
    • Fletes, R.1    Lazarus, J.M.2    Gage, J.3
  • 40
    • 0023760249 scopus 로고
    • Successful prevention of an anaphylactoid reaction to iron dextran
    • Altman LC, Petersen PE: Successful prevention of an anaphylactoid reaction to iron dextran. Ann Intern Med 1988; 109:346–347
    • (1988) Ann Intern Med , vol.109 , pp. 346-347
    • Altman, L.C.1    Petersen, P.E.2
  • 41
    • 0034007116 scopus 로고    scopus 로고
    • Successful administration of iron dextran in a patient who experienced a life threatening reaction to intravenous iron dextran
    • Hickman MA, Bernstein IL, Palascak JE: Successful administration of iron dextran in a patient who experienced a life threatening reaction to intravenous iron dextran. Ann Allergy Asthma Immunol 2000; 84:262–263
    • (2000) Ann Allergy Asthma Immunol , vol.84 , pp. 262-263
    • Hickman, M.A.1    Bernstein, I.L.2    Palascak, J.E.3
  • 42
    • 0036630323 scopus 로고    scopus 로고
    • Lack of reaction to ferric gluconate in hemodialysis patients with a history of severe reaction to iron dextran
    • Bastani B, Rahman S, Gellens M: Lack of reaction to ferric gluconate in hemodialysis patients with a history of severe reaction to iron dextran. ASAIO J 2002; 48:404–406
    • (2002) ASAIO J , vol.48 , pp. 404-406
    • Bastani, B.1    Rahman, S.2    Gellens, M.3
  • 43
    • 85031093614 scopus 로고    scopus 로고
    • Two case reports of desensitization in patients with hypersensitivity to iron
    • Chapman E, Leal D, Alvarez L, et al.: Two case reports of desensitization in patients with hypersensitivity to iron. World Allergy Organ J 2017; 10:38
    • (2017) World Allergy Organ J , vol.10 , pp. 38
    • Chapman, E.1    Leal, D.2    Alvarez, L.3
  • 44
    • 84885419540 scopus 로고    scopus 로고
    • Serious Hazards of Transfusion (SHOT) haemovigilance and progress is improving transfusion safety
    • Bolton-Maggs PH, Cohen H: Serious Hazards of Transfusion (SHOT) haemovigilance and progress is improving transfusion safety. Br J Haematol 2013; 163:303–314
    • (2013) Br J Haematol , vol.163 , pp. 303-314
    • Bolton-Maggs, P.H.1    Cohen, H.2
  • 45
    • 84909961726 scopus 로고    scopus 로고
    • [Last accessed August 29, 2018] Available from
    • Health Canada: Drug Product Database Online Query. [Last accessed: August 29, 2018] Available from: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp.
    • Drug Product Database Online Query
  • 46
    • 85030167806 scopus 로고    scopus 로고
    • Mechanisms, cofactors, and augmenting factors involved in anaphylaxis
    • Muñoz-Cano R, Pascal M, Araujo G, et al.: Mechanisms, cofactors, and augmenting factors involved in anaphylaxis. Front Immunol 2017; 8:1193
    • (2017) Front Immunol , vol.8 , pp. 1193
    • Muñoz-Cano, R.1    Pascal, M.2    Araujo, G.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.